CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma (HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the mechanisms underlying resistance have not been fully clarified. Here we report that a circular RNA, circRNA-SORE (a circular RNA upregulated in so rafenib-re sistant HCC cells), plays a significant role in sorafenib resistance in HCC. We found that circRNA-SORE is upregulated in sorafenib-resistant HCC cells and depletion of circRNA-SORE substantially increases the cell-killing ability of sorafenib. Further studies revealed that circRNA-SORE binds the master oncogenic protein YBX1 in the cytoplasm, which prevents YBX1 nuclear interaction with the E3 ubiquitin ligase PRP19 and thus blocks PRP19-mediated YBX1 degradation. Moreover, our in vitro and in vivo results suggest that circRNA-SORE is transported by exosomes to spread sorafenib resistance among HCC cells. Using different HCC mouse models, we demonstrated that silencing circRNA-SORE by injection of siRNA could substantially overcome sorafenib resistance. Our study provides a proof-of-concept demonstration for a potential strategy to overcome sorafenib resistance in HCC patients by targeting circRNA-SORE or YBX1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhang, H., Deng, T., Ge, S., Liu, Y., Bai, M., Zhu, K., Fan, Q., Li, J., Ning, T., Tian, F., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0619-z · Cited by 303
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx247 · Cited by 9,849
Circular RNAs are a large class of animal RNAs with regulatory potency
Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., Maier, L., Mackowiak, S. D., Gregersen, L. H., Munschauer, M., et al. (2013) · Nature · doi:10.1038/nature11928 · Cited by 7,990 · cited 3×
“Based on highthroughput sequencing and novel computational approaches, circRNAs derived from exons or introns are now recognized as widespread and diverse endogenous eukaryotic ncRNAs that participate in various cancer-related processes.(5,6,35) CircRNAs have a covalently closed-loop structure with neither 5′ to 3′ po…”
BackgroundNatural RNA circles function as efficient microRNA sponges
Hansen, T. B., Jensen, T. I., Clausen, B. H., Bramsen, J. B., Finsen, B., Damgaard, C. K., & Kjems, J. (2013) · Nature · doi:10.1038/nature11993 · Cited by 7,985
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Membrane vesicles as conveyors of immune responses
Théry, C., Ostrowski, M., & Segura, E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2567 · Cited by 3,882
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Extracellular vesicles: biology and emerging therapeutic opportunities
EL Andaloussi, S., Mäger, I., Breakefield, X. O., & Wood, M. J. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3978 · Cited by 3,571
circRNA biogenesis competes with pre-mRNA splicing
Ashwal-Fluss, R., Meyer, M., Pamudurti, N. R., Ivanov, A., Bartok, O., Hanan, M., Evantal, N., Memczak, S., Rajewsky, N., & Kadener, S. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.019 · Cited by 3,083 · cited 3×
“CircRNA-SORE functions by binding to YBX1 protein One of the best-known functions of circRNA is to interrupt the mRNA splicing of its host gene.(15) As exon-derived circRNAs and their host mRNAs are derived from the same pre-mRNA, circRNA can interrupt the splicing of its host mRNA, and the canonical premRNA splicing…”
BackgroundExon-intron circular RNAs regulate transcription in the nucleus
Li, Z., Huang, C., Bao, C., Chen, L., Lin, M., Wang, X., Zhong, G., Yu, B., Hu, W., Dai, L., et al. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2959 · Cited by 2,905
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Circular intronic long noncoding RNAs
Zhang, Y., Zhang, X.-O., Chen, T., Xiang, J.-F., Yin, Q.-F., Xing, Y.-H., Zhu, S., Yang, L., & Chen, L.-L. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.017 · Cited by 2,221 · cited 1×
“Based on highthroughput sequencing and novel computational approaches, circRNAs derived from exons or introns are now recognized as widespread and diverse endogenous eukaryotic ncRNAs that participate in various cancer-related processes.(5,6,35) CircRNAs have a covalently closed-loop structure with neither 5′ to 3′ po…”
BackgroundCircular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis
Li, Y., Zheng, Q., Bao, C., Li, S., Guo, W., Zhao, J., Chen, D., Gu, J., He, X., & Huang, S. (2015) · Cell Research · doi:10.1038/cr.2015.82 · Cited by 2,204
Zheng, Q., Bao, C., Guo, W., Li, S., Chen, J., Chen, B., Luo, Y., Lyu, D., Li, Y., Shi, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms11215 · Cited by 2,043
Self-citationMolecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2
Du, W. W., Yang, W., Liu, E., Yang, Z., Dhaliwal, P., & Yang, B. B. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw027 · Cited by 1,699 · cited 2×
“For example, circRNAFOXO3 was shown to inhibit cell cycle progression by forming ternary complexes with p21 and CDK2.(8) Exosomes are a class of extracellular vesicles that play vital roles in numerous physiological and pathological processes, such as the maintenance of normal physiology, regulation of immune response…”
BackgroundQu, L., Ding, J., Chen, C., Wu, Z.-J., Liu, B., Gao, Y., Chen, W., Liu, F., Sun, W., Li, X.-F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.004 · Cited by 1,117
Circular RNA and miR-7 in Cancer
Hansen, T. B., Kjems, J., & Damgaard, C. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1568 · Cited by 918
FDA-Approved Oligonucleotide Therapies in 2017
Stein, C. A., & Castanotto, D. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.023 · Cited by 608
Circular RNAs: splicing’s enigma variations
Hentze, M. W., & Preiss, T. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.53 · Cited by 455
Targeted Therapies for Hepatocellular Carcinoma
Villanueva, A., & Llovet, J. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.006 · Cited by 449
Abou-Alfa, G. K., Johnson, P., Knox, J. J., Capanu, M., Davidenko, I., Lacava, J., Leung, T., Gansukh, B., & Saltz, L. B. (2010) · JAMA · doi:10.1001/jama.2010.1672 · Cited by 448
Lu, Z., Zuo, B., Jing, R., Gao, X., Rao, Q., Liu, Z., Qi, H., Guo, H., & Yin, H. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.019 · Cited by 361
Chen, J., Jin, R., Zhao, J., Liu, J., Ying, H., Yan, H., Zhou, S., Liang, Y., Huang, D., Liang, X., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.019 · Cited by 251
Self-citationMaréchal, A., Li, J.-M., Ji, X. Y., Wu, C.-S., Yazinski, S. A., Nguyen, H. D., Liu, S., Jiménez, A. E., Jin, J., & Zou, L. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.11.002 · Cited by 249
Exosome miR‐335 as a novel therapeutic strategy in hepatocellular carcinoma
Wang, F., Li, L., Piontek, K., Sakaguchi, M., & Selaru, F. M. (2018) · Hepatology · doi:10.1002/hep.29586 · Cited by 231
YB-1: oncoprotein, prognostic marker and therapeutic target?
Lasham, A., Print, C. G., Woolley, A. G., Dunn, S. E., & Braithwaite, A. W. (2013) · Biochemical Journal · doi:10.1042/bj20121323 · Cited by 206
Extracellular vesicles – vehicles that spread cancer genes
Rak, J., & Guha, A. (2012) · BioEssays · doi:10.1002/bies.201100169 · Cited by 184
Splicing and beyond: The many faces of the Prp19 complex
Chanarat, S., & Sträßer, K. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.05.023 · Cited by 157
Qu, Z., Wu, J., Wu, J., Luo, D., Jiang, C., & Ding, Y. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0430-z · Cited by 156
The emerging role and clinical implication of human exonic circular RNA
Lyu, D., & Huang, S. (2016) · RNA Biology · doi:10.1080/15476286.2016.1227904 · Cited by 136
Targeting the Y/CCAAT box in cancer: YB-1 (YBX1) or NF-Y?
Dolfini, D., & Mantovani, R. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.13 · Cited by 116
Xu, J., Lin, H. M., Li, G., Sun, Y., Chen, J., Shi, L., Cai, X., & Chang, C. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.07.013 · Cited by 96
Self-citationZhu, A. X., Baron, A. D., Malfertheiner, P., Kudo, M., Kawazoe, S., Pezet, D., Weissinger, F., Brandi, G., Barone, C. A., Okusaka, T., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4115 · Cited by 88
The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy
Moore, C., Kosgodage, U. S., Lange, S., & Inal, J. M. (2017) · International Journal of Cancer · doi:10.1002/ijc.30672 · Cited by 76
Interaction of U-box E3 ligase SNEV with PSMB4, the β7 subunit of the 20 S proteasome
LÖSCHER, M., FORTSCHEGGER, K., RITTER, G., WOSTRY, M., VOGLAUER, R., SCHMID, J. A., WATTERS, S., RIVETT, A. J., AJUH, P., LAMOND, A. I., et al. (2005) · Biochemical Journal · doi:10.1042/bj20041517 · Cited by 55
Xu, J., Lin, H. M., Li, G., Sun, Y., Shi, L., Ma, W., Chen, J., Cai, X., & Chang, C. (2016) · International Journal of Cancer · doi:10.1002/ijc.30446 · Cited by 33
Self-citationMouse Homologue of Yeast Prp19 Interacts with Mouse SUG1, the Regulatory Subunit of 26S Proteasome
Sihn, C.-R., Cho, S. Y., Lee, J. H., Lee, T. R., & Kim, S. H. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.134 · Cited by 21
Cited by
Targeting non-coding RNAs to overcome cancer therapy resistance
Chen, B., Dragomir, M. P., Yang, C., Li, Q., Horst, D., & Calin, G. A. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00975-3 · Cited by 435
Mechanisms of drug resistance in HCC
Ladd, A. D., Duarte, S., Sahin, I., & Zarrinpar, A. (2024) · Hepatology · doi:10.1097/hep.0000000000000237 · Cited by 363
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 294
Conn, V. M., Chinnaiyan, A. M., & Conn, S. J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00721-7 · Cited by 258
Shu, G., Lu, X., Pan, Y., Cen, J., Huang, K., Zhou, M., Lu, J., Dong, J., Han, H., Chen, W., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02678-7 · Cited by 35
Metadata
- Authors
- Xu, J., Ji, L., Liang, Y., Wan, Z., Zheng, W., Song, X., Gorshkov, K., Sun, Q., Lin, H., Zheng, X., Chen, J., Jin, R.-A., Liang, X., & Cai, X.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2020-12-26
- Volume
- 5
- Issue
- 1
- Pages
- 298-298
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W3117640930
- Cited by
- 495
- References
- 41
- FWCI
- 19.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.